Tag Archives: Warren Woessner

NATURE/BIOTECHNOLOGY SUMMARIZES ARIAD DECISION

A recent article by Ken Garber in Nature/Biotechnology, 27, 494 (June 2009) summarizes the recent Federal Circuit decision invalidating the claims-in-suit in Ariad v. Lilly for failure to meet the WDR. (See my post of April 13, 2009 “Federal Circuit … Continue reading

Posted in Written Description Requirements (WDR) | Tagged , , , , , , , , , , , , | Leave a comment

ABBOTT LABS. v. SANDOZ, INC. – ONE RULE FITS ALL?

Or “what’s sauce for the goose is sauce for the gander”? Posts and pens have been busy reporting that the Federal Circuit, en banc, overruled Scripps v. Genentech, and ended the debate over whether a product-by-process claims should be construed … Continue reading

Posted in Claim Interpretation | Tagged , , , , , , | Leave a comment

GETTING TO ALLOWANCE – SEVEN HABITS OF HIGHLY EFFECTIVE CLIENTS

1. Tell Your Patent Attorney What You Want Your Patent To Do. IP attorneys are continuously told that we should be business partners with our clients, not just patent scribes. But there are lots of ways to protect an invention. … Continue reading

Posted in USPTO Practice and Policy | Tagged , , , , , , , , | Leave a comment

BIO/CHEM/PHARMA CUSTOMER PARTNERSHIP CONTINUES – REPORT FROM 3/3/09 MEETING

Although this report (see link below) is of the March meeting, I hope to have current reports of meetings soon after they occur – if they continue to occur. It also gives me a chance to visit memory lane. In … Continue reading

Posted in USPTO Practice and Policy | Tagged , , , , | Leave a comment